Hunan Saitumofei

Hunan Saitumofei Medical Treatment Technology is a Chinese medical device company and a subsidiary of WORK Medical Technology Group LTD (Nasdaq: WOK). Based in Changsha, the company specializes in the development and manufacturing of Class II medical devices, with a focus on integrating artificial intelligence into clinical diagnostics. Its flagship product, the AI-Automated Human Blood Cell Morphology Analyzer (CM-B600), utilizes deep-learning algorithms and high-speed digital imaging to automate white blood cell differential counts and morphological analysis of red blood cells and platelets. The device received manufacturing approval from the Hunan Provincial Medical Products Administration in late 2025, with production slated for the first half of 2026. By streamlining labor-intensive microscopic examinations, Hunan Saitumofei aims to enhance diagnostic accuracy and efficiency in hematology and oncology departments. The company has established strategic distribution partnerships, including an exclusive agreement with Shanghai Benke Medical Technology, to commercialize its AI-driven solutions across China.